March 29, 2021
Astellas Pharma said on March 26 that it has received US FDA approval for its overactive bladder (OAB) drug Myrbetriq (mirabegron extended-release tablets) for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients. The approval was granted for the...read more